Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Imidazo purine diones were another cluster of compounds iden
2021-04-17

1-Imidazo[2,1-]purine-2,4(3,8)-diones were another cluster of compounds identified from the Chembridge screen (). A benzyl group at the R2 position was preferred over a phenyl or 2-phenylpropyl (. and ), and -substitution of the benzyl group increased potency to the nanomolar level ( IC=0.20μM . ).
-
br Conclusion In vivo pharmacokinetic studies
2021-04-17

Conclusion In vivo pharmacokinetic studies showed that dasatinib monohydrate pretreatment significantly decreased the blood level of CsA in rats, which was most probably due to the induction of CYP3A2 isoenzymes. The nilotinib pre-treatment had no significant effects on cyclosporine pharmacokinet
-
HOBt Alvocidib flavopiridol is a piperidine chromenone http
2021-04-17

Alvocidib (flavopiridol) is a piperidine-chromenone derivative (Fig. 6D) that is not FDA approved, but is in clinical trials for breast, endometrial, and several other cancers and hematological malignancies (Table 4) [[100], [101], [102], [103], [104]]. This drug targets CDK9 (IC50 = 3.2 nM) and CDK
-
Similarly to the chemokine CCL the level of the chemokine
2021-04-17

Similarly to the chemokine CCL-5, the level of the chemokine SDF-1 in the groups of individuals with APD did not differ from its level in the control group. However, a slight increase in the level of this chemokine was recorded in the group of women and men with APD and PTSD as compared with the cor
-
Adapalene sodium salt It is well known that the tumor
2021-04-16

It is well known that the tumor suppressor p53 plays an important role in regulating the Adapalene sodium salt and cellular senescence [43,46,48]. For example, FOXO4 could interact with P53, which selectively induced apoptosis in senescent cells [48]. In addition, loss of MECP2 was found to lead to
-
These data indicate that in the
2021-04-16

These data indicate that, in the context of the N-terminal 42 amino acids of p53, threonine 18 is a substrate for phosphorylation by CK1 as mediated by prior phosphorylation of serine 15. To determine whether this is a property of full length p53, GST-p53 fusion proteins comprising the full length p
-
Nowadays it is possible to detect the AChE inhibitors
2021-04-16

Nowadays it is possible to detect the AChE inhibitors by several methods such as gas chromatography-mass spectrometry [11], ion mobility spectrometry [12] and lab-on-chip devices [13,14]. However, almost all instrumental detection techniques that are able to conclusively determine the presence of th
-
To our knowledge this study is the first to construct
2021-04-16

To our knowledge, this study is the first to construct a whole-body transcriptome of D. variabilis. Most of the data currently accessible in NCBI are derived from a midgut EST database consisting of 1679 transcripts (Anderson et al., 2008) and about 20,000 mRNA sequences from the testis-vas deferen
-
br Materials and methods br Data and statistical
2021-04-16

Materials and methods Data and statistical analysis The results were expressed as mean ± SEM. One-way analysis of variance (ANOVA), followed by Bonferroni's post-test or unpaired Student's t-test were used to determine significant differences between groups. The program used for statistical an
-
Currently phosphodiesterase type PDE inhibitors are used wid
2021-04-16

Currently, phosphodiesterase type 5 (PDE-5) inhibitors are used widely as the first- line oral treatment for erectile dysfunction of varying causes. Radical prostatectomy for the treatment of prostate cancer is frequently associated with erectile dysfunction, and this type of erectile dysfunction is
-
thyrotropin receptor br In addition to the classic nuclear g
2021-04-16

In addition to the classic nuclear genomic action, estrogens have been found to induce rapid effects occurring within minutes following administration. These effects are mediated through a subpopulation of estrogen receptors associated with the plasma membrane, a process usually termed “membrane-i
-
br The modulation of ER from
2021-04-16

The modulation of ERα: from SERMs to TSECs Continued efforts to provide women with efficacious menopausal therapies have generated interest in the development of selective read 108 synthesis receptor modulators (SERMs). Similar to estrogens, SERMs have been shown to bind to ERs with high affinit
-
Further proof is required as to whether ER
2021-04-16

Further proof is required as to whether ER membrane receptors play a role in the maintenance of bone mass. It is also possible that other non-genomic pathways may be involved. Nevertheless, whatever the precise mechanism of action of estrogens may be, the imbalance between bone formation and resorpt
-
Amoxapine br Materials and methods br Results br Discussion
2021-04-16

Materials and methods Results Discussion The EP4 Amoxapine for PGE2 is similar to the EP1, EP2 and EP3 receptors in that they all have seven transmembrane segments and are coupled to Gα subunits of heterotrimeric G proteins, with a different Gα subunit for each receptor (Sugimoto and Narum
-
br Conflict of interest br Acknowledgements We wish to
2021-04-16

Conflict of interest Acknowledgements We wish to thank Arantza Pérez (University of the Basque Country) for her technical contribution to this study. This work was supported by grants from the Jesús Gangoiti-Barrera Foundation, Gobierno Vasco (GIC07/84), MEC () and SAIOTEK (SA-2008/00046).
16668 records 705/1112 page Previous Next First page 上5页 701702703704705 下5页 Last page